Side-by-side comparison of AI visibility scores, market position, and capabilities
AI care enablement platform resolving 85% of patient inquiries within one day; $12M Series A from Molten Ventures helping clinics manage NHS and value-based care patient caseloads.
Anima is a care enablement platform that uses AI to help clinical teams manage patient caseloads more efficiently — enabling practices, clinics, and healthcare systems to handle more patient inquiries with the same clinical staff by triaging, routing, and pre-processing patient messages, symptoms, and administrative requests before they reach clinicians. Founded as a Y Combinator W21 graduate, Anima raised $14.5 million total including a $12 million Series A in early 2024 led by Molten Ventures with Hummingbird, achieving a benchmark of resolving 85% of patient inquiries within one day.\n\nAnima's platform integrates with existing EHR systems and clinical workflows — when patients submit messages or requests, Anima's AI layer categorizes the urgency, extracts relevant clinical context from the patient record, and routes to the appropriate care team member with pre-populated response templates and suggested actions. Administrative inquiries (prescription refills, appointment requests, test result questions) are handled with AI-assisted responses that clinicians can review and approve rapidly rather than composing from scratch. This reduces the cognitive load of clinical inbox management that contributes to physician burnout.\n\nIn 2025, Anima competes in the clinical workflow automation and care management platform market with Klara (patient communication), Luma Health (care orchestration), Healthie, and AI-powered EHR tools from Epic and athenahealth for clinical team productivity and patient communication. The UK National Health Service (NHS) has been a key market for Anima, given the NHS's acute GP workload crisis and the need for digital tools that help manage the high volume of patient contacts with limited clinical capacity. The 2025 strategy focuses on expanding within NHS primary care networks, growing in US value-based care organizations where managing population health efficiently is financially incentivized, and deepening AI capabilities for clinical decision support.
AI chemical reaction optimization with 95% accuracy for drug discovery synthesis parameters; $4.5M from Khosla Ventures and YC competing to automate pharmaceutical process chemistry development.
Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists with AI systems that determine optimal reaction parameters (temperature, solvent, catalyst, concentration) for new chemical synthesis routes, achieving 95% accuracy in suggesting effective conditions for small-scale trials. Founded in 2023 and backed by Khosla Ventures, 468 Capital, 500 Global, and Y Combinator with $4.5 million raised including a $4 million seed round in April 2024, Yoneda Labs brings mathematical category theory foundations (the name references Yoneda's lemma in category theory) to chemistry AI.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.